167 related articles for article (PubMed ID: 24755543)
21. Vitamin K1 cream significantly reduces incidence and severity of cetuximab-related acneiform skin rash in women: a post hoc analysis of the EVITA trial.
Gaiser MR; Lorenzen S; Merx K; Trojan J; Ocvirk J; Ettrich TJ; Al-Batran SE; Schulz H; Homann N; Feustel HP; Schatz M; Kripp M; Schulte N; Heeger S; Vlassak S; Koch W; Hofheinz RD
Ann Oncol; 2018 Dec; 29(12):2393-2395. PubMed ID: 30307464
[No Abstract] [Full Text] [Related]
22. Topical therapy with nadifloxacin cream and prednicarbate cream improves acneiform eruptions caused by the EGFR-inhibitor cetuximab - A report of 29 patients.
Katzer K; Tietze J; Klein E; Heinemann V; Ruzicka T; Wollenberg A
Eur J Dermatol; 2010; 20(1):82-4. PubMed ID: 19797039
[TBL] [Abstract][Full Text] [Related]
23. Management of skin toxicity associated with cetuximab treatment in combination with chemotherapy or radiotherapy.
Pinto C; Barone CA; Girolomoni G; Russi EG; Merlano MC; Ferrari D; Maiello E; ;
Oncologist; 2011; 16(2):228-38. PubMed ID: 21273511
[TBL] [Abstract][Full Text] [Related]
24. Cetuximab monotherapy in advanced cervical cancer: a retrospective study with five patients.
Hertlein L; Lenhard M; Kirschenhofer A; Kahlert S; Mayr D; Burges A; Friese K
Arch Gynecol Obstet; 2011 Jan; 283(1):109-13. PubMed ID: 20180130
[TBL] [Abstract][Full Text] [Related]
25. Cetuximab-induced acneiform eruption and the response to isotretinoin.
Vezzoli P; Marzano AV; Onida F; Alessi E; Galassi B; Tomirotti M; Berti E
Acta Derm Venereol; 2008; 88(1):84-6. PubMed ID: 18176767
[No Abstract] [Full Text] [Related]
26. Grover's disease induced by cetuximab.
Tscharner GG; Bühler S; Borner M; Hunziker T
Dermatology; 2006; 213(1):37-9. PubMed ID: 16778425
[TBL] [Abstract][Full Text] [Related]
27. Efficacy, tolerability and impact on quality of life of clindamycin phosphate and benzoyl peroxide for the treatment of cetuximab-associated acneiform eruption in patients with metastatic colorectal cancer.
Vaccaro M; Guarneri F; Borgia F; Pollicino A; Altavilla G; Cannavò SP
J Dermatolog Treat; 2016; 27(2):148-52. PubMed ID: 26313697
[TBL] [Abstract][Full Text] [Related]
28. Correlation of cetuximab-induced skin rash and outcomes of solid tumor patients treated with cetuximab: a systematic review and meta-analysis.
Abdel-Rahman O; Fouad M
Crit Rev Oncol Hematol; 2015 Feb; 93(2):127-35. PubMed ID: 25139841
[TBL] [Abstract][Full Text] [Related]
29. Prognostic Significance of Cutaneous Adverse Events Associated With Pembrolizumab Therapy.
Lo JA; Fisher DE; Flaherty KT
JAMA Oncol; 2015 Dec; 1(9):1340-1. PubMed ID: 26270186
[No Abstract] [Full Text] [Related]
30. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.
Bonner JA; Harari PM; Giralt J; Cohen RB; Jones CU; Sur RK; Raben D; Baselga J; Spencer SA; Zhu J; Youssoufian H; Rowinsky EK; Ang KK
Lancet Oncol; 2010 Jan; 11(1):21-8. PubMed ID: 19897418
[TBL] [Abstract][Full Text] [Related]
31. Cetuximab-induced cutaneous toxicity.
Tomková H; Kohoutek M; Zábojníková M; Pospísková M; Ostrízková L; Gharibyar M
J Eur Acad Dermatol Venereol; 2010 Jun; 24(6):692-6. PubMed ID: 19925598
[TBL] [Abstract][Full Text] [Related]
32. Monoclonal antibody-induced papulopustular rash: Clinical course, communication to health-care professionals and reactive measures as reported by patients.
Cignola S; Gonella S; Alessandra B; Palese A
Eur J Oncol Nurs; 2016 Feb; 20():133-9. PubMed ID: 26187661
[TBL] [Abstract][Full Text] [Related]
33. A prospective randomized trial of topical pimecrolimus for cetuximab-associated acnelike eruption.
Scope A; Lieb JA; Dusza SW; Phelan DL; Myskowski PL; Saltz L; Halpern AC
J Am Acad Dermatol; 2009 Oct; 61(4):614-20. PubMed ID: 19646778
[TBL] [Abstract][Full Text] [Related]
34. Prophylactic Effect of Oral Minocycline in Combination with Topical Steroid and Skin Care Against Panitumumab-induced Acneiform Rash in Metastatic Colorectal Cancer Patients.
Yamada M; Iihara H; Fujii H; Ishihara M; Matsuhashi N; Takahashi T; Yoshida K; Itoh Y
Anticancer Res; 2015 Nov; 35(11):6175-81. PubMed ID: 26504047
[TBL] [Abstract][Full Text] [Related]
35. Acneiform eruption following molecular targeted chemotherapy.
Vaccaro M; Barbuzza O; Pollicino A; Guarneri C
Intern Med J; 2011 Apr; 41(4):361-2. PubMed ID: 21507168
[No Abstract] [Full Text] [Related]
36. Severe acneiform eruption induced by cetuximab (Erbitux).
Lee JE; Lee SJ; Lee HJ; Lee JH; Lee KH
Yonsei Med J; 2008 Oct; 49(5):851-2. PubMed ID: 18972607
[TBL] [Abstract][Full Text] [Related]
37. Two cases of acneiform eruption induced by inhibitor of epidermal growth factor receptor.
Gencoglan G; Ceylan C
Skin Pharmacol Physiol; 2007; 20(5):260-2. PubMed ID: 17641540
[TBL] [Abstract][Full Text] [Related]
38. Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption.
Scope A; Agero AL; Dusza SW; Myskowski PL; Lieb JA; Saltz L; Kemeny NE; Halpern AC
J Clin Oncol; 2007 Dec; 25(34):5390-6. PubMed ID: 18048820
[TBL] [Abstract][Full Text] [Related]
39. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines.
Lenz HJ; Van Cutsem E; Khambata-Ford S; Mayer RJ; Gold P; Stella P; Mirtsching B; Cohn AL; Pippas AW; Azarnia N; Tsuchihashi Z; Mauro DJ; Rowinsky EK
J Clin Oncol; 2006 Oct; 24(30):4914-21. PubMed ID: 17050875
[TBL] [Abstract][Full Text] [Related]
40. Cutaneous toxicities of antineoplastic agents: data from a large cohort of Greek patients.
Nikolaou V; Voudouri D; Tsironis G; Charpidou A; Stamoulis G; Triantafyllopoulou I; Panoutsopoulou I; Xidakis E; Bamias A; Samantas E; Aravantinos G; Gogas H; Rigopoulos D; Syrigos K; Stratigos A
Support Care Cancer; 2019 Dec; 27(12):4535-4542. PubMed ID: 30919155
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]